GRTS Stock Overview
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Gritstone bio, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.38 |
52 Week High | US$3.33 |
52 Week Low | US$1.14 |
Beta | 0.40 |
1 Month Change | 10.19% |
3 Month Change | 32.22% |
1 Year Change | -2.46% |
3 Year Change | -82.44% |
5 Year Change | -78.23% |
Change since IPO | -83.29% |
Recent News & Updates
Recent updates
Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%
Aug 14Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst
Sep 26Gritstone reaches six-month high on publication of data for cancer vaccine
Aug 16Gritstone bio announces $80M credit facility
Jul 21Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?
Jul 07Gritstone bio: Potential To Advance Colorectal Cancer Treatment
Jul 05Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation
Jun 14Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates
Mar 17We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate
Mar 05Gritstone: Why The Stock Fell On Positive Data
Jan 18Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business
Nov 23Gritstone Poised To Dominate mRNA Market
Nov 08Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation
May 26Gritstone Oncology EPS beats by $0.41, beats on revenue
May 06Gritstone files for mixed shelf offering of up to $690M
Jan 29Gritstone Oncology +9.3% AH, EcoR1 discloses ~10% stake in company
Jan 04Gritstone Oncology announces $125M in private placement financings
Dec 28Here's Why Gritstone Oncology (NASDAQ:GRTS) Must Use Its Cash Wisely
Dec 24Shareholder Returns
GRTS | US Biotechs | US Market | |
---|---|---|---|
7D | -1.2% | -2.1% | -0.1% |
1Y | -2.5% | 10.4% | 28.4% |
Return vs Industry: GRTS underperformed the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: GRTS underperformed the US Market which returned 28.4% over the past year.
Price Volatility
GRTS volatility | |
---|---|
GRTS Average Weekly Movement | 18.2% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GRTS's share price has been volatile over the past 3 months.
Volatility Over Time: GRTS's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 231 | Andrew Allen | https://gritstonebio.com |
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.
Gritstone bio, Inc. Fundamentals Summary
GRTS fundamental statistics | |
---|---|
Market cap | US$233.40m |
Earnings (TTM) | -US$138.49m |
Revenue (TTM) | US$16.34m |
14.3x
P/S Ratio-1.7x
P/E RatioIs GRTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GRTS income statement (TTM) | |
---|---|
Revenue | US$16.34m |
Cost of Revenue | US$127.18m |
Gross Profit | -US$110.84m |
Other Expenses | US$27.65m |
Earnings | -US$138.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.41 |
Gross Margin | -678.16% |
Net Profit Margin | -847.34% |
Debt/Equity Ratio | 77.4% |
How did GRTS perform over the long term?
See historical performance and comparison